Histone Deacetylase 8 - Pipeline Review, H2 2020

July 2020 | 27 pages | ID: H5AB530EA95CEN
Global Markets Direct

Abstracts

Histone Deacetylase 8 - Pipeline Review, H2 2020

SUMMARY

According to the recently published report 'Histone Deacetylase 8 - Pipeline Review, H2 2020'; Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) pipeline Target constitutes close to 5 molecules.
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Histone deacetylase 8 is an enzyme encoded by the HDAC8 gene. It is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones. It plays an important role in transcriptional regulation, cell cycle progression and developmental events.
The report 'Histone Deacetylase 8 - Pipeline Review, H2 2020' outlays comprehensive information on the Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I and Preclinical stages are 1 and 4 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal and Musculoskeletal Disorders which include indications Alzheimer's Disease, Bone Disorders, Breast Cancer, Colon Cancer, Glioblastoma Multiforme (GBM), Liver Fibrosis, Multiple Myeloma (Kahler Disease), Prostate Cancer and Triple-Negative Breast Cancer (TNBC).

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)
• The report reviews Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
• The report assesses Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Overview
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
Jubilant Therapeutics Inc
NatureWise Biotech & Medicals Corp
Oceanyx Pharmaceuticals Inc
Shuttle Pharmaceuticals Inc
Zhejiang Hisun Pharmaceutical Co Ltd
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Drug Profiles
JBI-097 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
largazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NBM-BMX - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-1161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Jubilant Therapeutics Inc, H2 2020
Pipeline by NatureWise Biotech & Medicals Corp, H2 2020
Pipeline by Oceanyx Pharmaceuticals Inc, H2 2020
Pipeline by Shuttle Pharmaceuticals Inc, H2 2020
Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

Jubilant Therapeutics Inc
NatureWise Biotech & Medicals Corp
Oceanyx Pharmaceuticals Inc
Shuttle Pharmaceuticals Inc
Zhejiang Hisun Pharmaceutical Co Ltd